GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Lakewood-Amedex Biotherapeutics Inc. Common Stock LABT · USD

US listing · 🇺🇸 United States

Compare

0.42

+8.21%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Lakewood-Amedex Biotherapeutics Inc. Common Stock

Its shares trade under the ticker LABT. It has been listed since 23 April 2026.

Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Listed since
23 Apr 2026
Head office
8031 COOPER CREEK BLVD., UNIVERSITY PARK, FL, 34201
Incorporated in
NV
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Lakewood-Amedex Biotherapeutics develops innovative antimicrobial products like Bisphosphocin for skin, bladder, and lung infections.
  • Nu-3, a topical antimicrobial for diabetic foot ulcers, is in Phase 2b clinical trials in the US market.
  • The company has a strong focus on clinical-stage biotechnology with a 2006 incorporation date in University Park.

Weaknesses

  • The company's clinical-stage status means it has not yet commercialized any products as of 2026.
  • Lakewood-Amedex Biotherapeutics has no products approved for market use in the US healthcare sector.
  • The company's name change from Lakewood-Amedex Inc. to Biotherapeutics in June 2025 may cause brand confusion.

Opportunities

  • The US healthcare sector offers significant growth potential for antimicrobial treatments targeting skin, bladder, and lung infections.
  • Phase 2b trials for Nu-3 could lead to market entry in the diabetic foot ulcer treatment segment by 2027.
  • The company's focus on antimicrobial products aligns with rising global health priorities in the healthcare industry.

Threats

  • The US clinical trial process for antimicrobial products faces regulatory delays that could impact product timelines.
  • Competition in the antimicrobial market may intensify as other companies develop similar treatments.
  • The company's reliance on clinical-stage development exposes it to funding risks in the biotechnology sector.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.